|Bid||20.10 x 1300|
|Ask||20.10 x 900|
|Day's Range||19.33 - 21.25|
|52 Week Range||17.80 - 45.02|
|Beta (3Y Monthly)||3.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 4, 2019 - Mar 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.71|
Editas Medicine president and CEO Katrine Bosley discusses her company's gene editing technology and the future of medicine.
NEW YORK, NY / ACCESSWIRE / January 23, 2019 / U.S. markets declined on Tuesday, breaking a streak of four consecutive days in the green, on growing trade concerns. Stocks were pressured lower on reports ...
Editas Medicine stock collapsed Tuesday — sending gene-editing stocks Crispr and Intellia also crashing — after Chief Executive Katrine Bosley said she will resign March 1.
Shares of Editas Medicine, Inc. plummeted 21% on Tuesday after the company announced that Chief Executive and President Katrine Bosley would be stepping down from her role, effective March 2019. Bosley also resigned from the company's board of directors, but will continue in an advisory role until the 2019 to facilitate a smooth transition, the company said. Cynthia Collins, a member of the company's board and former CEO of Human Longevity Inc., will serve as interim chief executive officer while the company searches for a permanent CEO. Bosley joined Editas as CEO in 2014, after working as an entrepreneur in residence at the Broad Institute and helming Avila Therapeutics, which was acquired by Celgene Corporation , as CEO. Shares of Editas Medicine, which develops therapies using the gene-editing technology Crispr, have fallen 9% in the year to date, while the iShares Nasdaq Biotechnology ETF has gained 12.8%. The S&P 500 has gained 5.5%.
Editas Medicine Inc. plunged as much as 22 percent after Katrine Bosley stepped down as CEO and also resigned from the board. The change was a “personal decision” by Bosley and is “occurring at a natural transition point for the company and also from a position of strength,” Cristi Barnett, an Editas spokeswoman, said in an emailed statement. Crispr Therapeutics AG dropped as much as 16 percent, the most since Dec. 21, after Citi analyst Yigal Nochomovitz cut his rating to sell, expressing concern about some of the company’s programs.
The news comes less than a month after the company's CFO, Andrew Hack, announced that he will also be leaving the company.
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Katrine Bosley has decided to step down from her role as President and CEO, effective March 1, 2019. Ms. Bosley also resigned from the Company’s Board of Directors.
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data demonstrating the pharmacology and specificity of EDIT-101, an experimental, CRISPR genome editing medicine being investigated for the treatment of Leber congenital amaurosis 10 (LCA10), a genetically-driven form of blindness. “We are thrilled Nature Medicine published our paper sharing the comprehensive set of pre-clinical data for EDIT-101 and our approach to creating CRISPR-based genome editing medicines,” said Charles Albright, Ph.D., Chief Scientific Officer, Editas Medicine. “The research presented in this important manuscript provided the foundation for our recently accepted Investigational New Drug (IND) application for EDIT-101 to treat LCA10, bringing us closer to the clinic and our goal of realizing the full potential of genome editing.
Editas Medicine (EDIT) closed at $26.03 in the latest trading session, marking a -0.69% move from the prior day.
The future of medicine involves the precise engineering of human cells. Turns out, that future may not include that promising CRISPR technique.
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...
It left fellow scientists, and the rest of the world, horrified that such a momentous leap had occurred in secret, with its potential for unintended consequences. Dr He Jiankui, the clinician behind the breakthrough, is now understood to be under investigation and under guard in China. Little is known about the twin girls, Lulu and Nana, whose genomes he manipulated.
Editas Medicine (EDIT) closed at $26.20 in the latest trading session, marking a -0.8% move from the prior day.
Pharmaceutical giants like Bayer and Novartis have dipped their toes into gene editing through collaborations, while others are adopting it in their own laboratories.
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
Editas Medicine, YY, Intel, Advanced Micro Devices and NVIDIA highlighted as Zacks Bull and Bear of the Day
Aerie (AERI) announces encouraging top-line results from its pilot phase II study of netarsudil ophthalmic solution in a Japan.